MAGNESIUM DEFICIENCY AND CARDIOVASCULAR DISEASES
- Authors: Shilov A.1, Abdullayeva A.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 23, No 7 (2012)
- Pages: 28-33
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115434
- ID: 115434
Cite item
Open Access
Access granted
Abstract
The paper describes the physiological mechanisms of magnesium involvement in the function of different human body systems at the level of a cell and subcellular structures. Magnesium deficiency, the incidence of which in clinical practice is as high as 70% and which appears as cardiovascular, cerebral, visceral, and muscular-tetanic syndromes, shows a clinical diversity. The pathophysiological mechanisms responsible for the implication of magnesium deficiency in the formation of insulin resistance (IR) as a key component of metabolic syndrome (MS) are discussed in detail. The authors present the results of combination treatment incorporating magnesium preparations (Magnerot 3 g/day) in 69 patients with MS. They also give the data of an analysis of the time course of changes in IR values, carbohydrate and lipid metabolic parameters, and blood rheological spectra.
Full Text
About the authors
A. Shilov
I.M. Sechenov First Moscow State Medical University
Email: melnik.m.v.@gmail.com
Professor MD
A. Abdullayeva
I.M. Sechenov First Moscow State Medical University
Email: melnik.m.v.@gmail.com
References
- Городецкий В.В., Талибов О.Б. Препараты магния в медицинской практике. Малая энциклопедия магния / М.: Медпрактика. - 2006.
- Громова О.А. Магний и пиридоксин: основы знаний. Новые технологии диагностики и коррекции дефицита магния. Обучающие программы Юнеско / М.: РСЦ Институт микроэлементов. - 2006; 3-176.
- Метаболический синдром / М.: МЕДпрес-информ. - 2007.
- Нечаева Г.М., Яковлев В.М., Друк И.В. и др. Нарушения ритма сердца при недифференцированной дисплазии соединительной ткани // Лечащий врач. - 2008; 6: 2-7.
- Рачин А.П., Сергеев А.В., Михейкина О.В. Дефицит магния: возможности применения препарата Магне В6 // Фарматека. - 2008; 5: 54-60.
- Шевченко О.П., Праскурничий Е.А., Шевченко А.О. Артериальная гипертония и ожирение / М.: Реофарм; - 2006.
- Barbato J., Zuckerbraun B., Overbaus M. et al. Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and metabolic syndrome // J. Physiol. Heart. Circ. - 2005; 289: 228-36.
- Caballero A. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease // Obes. Res. - 2003; 11: 1278-89.
- Dzau V., Antman E., Black H. et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) // Circulation. - 2006; 114: 2850-70.
- Jellinek H., Takacs E. Morphological aspects of the effects of orotic acid and magnesium // Arzneimittelforschung. - 1995; 45 (8): 836-42.
- Rabmouni K., Correia M., Haynes W. et al. Obesity -associated Hypertension. New insights into mechanisms // Hypertension. - 2005; 45: 9-14.
- Seelig M. Metabolic Sindrom-X. A complex of common diseases - diabetes, hypertension, heart disease, dyslipidemia and obesity - marked by insulin resistance and low magnesium/high calcium // Mineral. Res. Int. Tech. Prod. Infor. -2003; 1: 11.
Supplementary files
